{"entity":{"id":"nct07408089","kind":"trial","name":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer","aka":[],"tldr":"A phase 1 trial of BBI-940 run by Boundless Bio, Inc., terminated.","summary":"Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer is a phase 1 interventional study registered as NCT07408089 by Boundless Bio, Inc., with 8 participants enrolled, started 2026-02-25. Conditions recorded: Breast Cancer, Metastatic Breast Cancer and Advanced Breast Cancer. Interventions recorded: BBI-940 and Fulvestrant.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07408089","url":"https://clinicaltrials.gov/study/NCT07408089"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bbi-940"],"companies":["boundless-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07408089","phase":"1","setting":"An Open-Label, Multicenter, First-in-Human, Phase 1 Study of BBI-940 in Advanced or Metastatic Breast Cancer: Kinesin Oral Molecular Degrader for Oncology (KOMODO-1)","sponsor":"Boundless Bio, Inc.","enrolled":8,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07408089/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"bbi-940","kind":"drug","name":"BBI-940","route":"/drugs/bbi-940/"}],"company":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/"}]}}